Analytics
Resolved No on 1 Aug 2025.
The last daily price before settlement had No at 99.5%. Yes opened at 7.5% on 20 May 2025. Before it settled, the high was 7.5% on 20 May 2025 and the low 0.1% on 31 Jul 2025. $286.39K traded over the market's life.
83 wallets still hold shares. Winners redeem theirs after settlement, so what is left is mostly the losing side.
Polymarket record as of Aug 2, 8:53 AM UTC
Daily closes of the Yes price, Polymarket CLOB, 74 points, 20 May 2025 – 1 Aug 2025, chart shows 0%–10%
| Observed | Yes price |
|---|---|
| 20 May 2025 | 7.5% |
| 1 Aug 2025 | 0.5% |
Winners have redeemed their shares, so most of what is left is the losing side.
| Trader | Outcome | Shares |
|---|---|---|
| Important-Divide | Yes | 6.02K |
| Iceman7 | Yes | 6K |
| FrosenVerifiedVerified Polymarket profile | Yes | 4.3K |
| DeLondrex |
Every wallet's public record, and 80,000 ranked by lifetime P&L: Polymarket leaderboard
This market will resolve to "Yes" if definitive evidence confirming that Joe Biden was diagnosed with prostate cancer during his presidency (January 20, 2021, to January 20, 2025) is made public by July 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No". Statements from Joe Biden, his personal office, or doctors who treated Biden during his presidency, confirming a prostate cancer diagnosis during his presidency will qualify for a “Yes” resolution. Unverified allegations, anonymous claims, or documents not substantiated by credible reporting will not qualify. The primary resolution source will be a consensus of credible reporting, as well as official statements from Joe Biden’s office, medical professionals involved in his care, or U.S. government sources.
Official listing: polymarket.com/event/fact-check-biden-diagnosed-with-prostate-cancer-while-in-office
| Yes |
| 4.15K |
| SanCristo | Yes | 2.27K |
| Grogor | Yes | 1.57K |
| DBS1 | Yes | 1K |
| Automatic-Support | Yes | 1K |
| Alx.anto | Yes | 1K |
| Bruhhhhhhhh | Yes | 1K |
New to prediction markets? How to read a market page
